Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response

Molecules. 2018 May 26;23(6):1274. doi: 10.3390/molecules23061274.

Abstract

Background: Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance, leading to right ventricular failure and death. Recent studies have suggested that chronic inflammatory processes are involved in the pathogenesis of PAH. Several studies have demonstrated that betaine possesses outstanding anti-inflammatory effects. However, whether betaine exerts protective effects on PAH by inhibiting inflammatory responses in the lungs needs to be explored. To test our hypothesis, we aimed to investigate the effects of betaine on monocrotaline-induced PAH in rats and attempted to further clarify the possible mechanisms.

Methods: PAH was induced by monocrotaline (50 mg/kg) and oral administration of betaine (100, 200, and 400 mg/kg/day). The mean pulmonary arterial pressure, right ventricular systolic pressure, and right ventricle hypertrophy index were used to evaluate the development of PAH. Hematoxylin and eosin staining and Masson staining were performed to measure the extents of vascular remodeling and proliferation in fibrous tissue. Monocyte chemoattractant protein-1 (MCP-1) and endothelin-1 (ET-1) were also detected by immunohistochemical staining. Nuclear factor-κB (NF-κB), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β) were assessed by Western blot.

Results: This study showed that betaine improved the abnormalities in right ventricular systolic pressure, mean pulmonary arterial pressure, right ventricle hypertrophy index, and pulmonary arterial remodeling induced by monocrotaline compared with the PAH group. The levels of MCP-1 and ET-1 also decreased. Western blot indicated that the protein expression levels of NF-κB, TNF-α, and IL-1β significantly decreased (p < 0.01).

Conclusion: Our study demonstrated that betaine attenuated PAH through its anti-inflammatory effects. Hence, the present data may offer novel targets and promising pharmacological perspectives for treating monocrotaline-induced PAH.

Keywords: betaine; inflammatory response; pulmonary arterial hypertension.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Betaine / pharmacology*
  • Biomarkers
  • Chemokine CCL2 / metabolism
  • Cytokines / metabolism
  • Disease Models, Animal
  • Endothelin-1 / metabolism
  • Hemodynamics / drug effects
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / etiology*
  • Hypertension, Pulmonary / metabolism
  • Hypertension, Pulmonary / physiopathology*
  • Hypertrophy, Right Ventricular / drug therapy
  • Hypertrophy, Right Ventricular / etiology
  • Hypertrophy, Right Ventricular / pathology
  • Immunohistochemistry
  • Inflammation Mediators / metabolism
  • Male
  • Monocrotaline / adverse effects*
  • Myocardium / metabolism
  • Myocardium / pathology
  • NF-kappa B / metabolism
  • Pulmonary Artery / drug effects*
  • Pulmonary Artery / physiopathology*
  • Rats

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Biomarkers
  • CCL2 protein, human
  • Chemokine CCL2
  • Cytokines
  • Endothelin-1
  • Inflammation Mediators
  • NF-kappa B
  • Betaine
  • Monocrotaline